Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Direct-Acting Antiviral Therapy Boosts Survival for Infected HCC Patients

Publish date:: September 30, 2019

Key clinical point: Direct-acting antiviral therapy reduced risk of death, compared with no therapy in HCV-infected patients with a history of hepatocellular carcinoma.

Major finding: DAAs were associated with a significant reduction in risk of death among recovered HCC patients with HCV infections (HR, 0.54).

Study details: The data come from a retrospective study of 797 HCC patients with hepatitis C infection.

Disclosures: The study was funded in part by the National Cancer Institute and AbbVie. Dr. Singal disclosed relationships with companies including AbbVie, Gilead, Bayer, Eisai, Wako Diagnostics, Exact Sciences, Exelixis, Roche, Glycotest, and Bristol-Myers Squibb.

Citation:

Singal AG et al. Gastroenterology. 2019. doi: 10.1053/j.gastro.2019.07.040.

This Week's Must Reads

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

HCV screening risk factors in pregnant women need updating,

HCV testing/awareness successful as part of HIV integrated care,

Rare Mixed HCV Genotypes Found in Men Who Have Sex With Men,

HCV-viremic kidney transplantations had similar outcomes to non-HCV kidneys independent of recipient serostatus,

Must Reads in Hepatitis

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

HCV screening risk factors in pregnant women need updating,

HCV testing/awareness successful as part of HIV integrated care,

Rare Mixed HCV Genotypes Found in Men Who Have Sex With Men,

HCV-viremic kidney transplantations had similar outcomes to non-HCV kidneys independent of recipient serostatus,